Syndax PharmaceuticalsSNDX
SNDX
About: Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Employees: 184
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
129% more call options, than puts
Call options by funds: $18.1M | Put options by funds: $7.88M
44% more repeat investments, than reductions
Existing positions increased: 88 | Existing positions reduced: 61
27% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 26
25% more funds holding in top 10
Funds holding in top 10: 8 [Q4 2024] → 10 (+2) [Q1 2025]
2.53% more ownership
Funds ownership: 114.85% [Q4 2024] → 117.38% (+2.53%) [Q1 2025]
1% more funds holding
Funds holding: 215 [Q4 2024] → 218 (+3) [Q1 2025]
3% less capital invested
Capital invested by funds: $1.3B [Q4 2024] → $1.26B (-$41M) [Q1 2025]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$17
64%
upside
Avg. target
$26
146%
upside
High target
$35
238%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
UBS David Dai | 238%upside $35 | Buy Maintained | 15 Jul 2025 |
Goldman Sachs Corinne Johnson | 74%upside $18 | Buy Initiated | 10 Jul 2025 |
Scotiabank George Farmer | 64%upside $17 | Sector Perform Maintained | 6 May 2025 |
Guggenheim Michael Schmidt | 209%upside $32 | Buy Reiterated | 6 May 2025 |
Financial journalist opinion
Based on 5 articles about SNDX published over the past 30 days
Positive
Zacks Investment Research
19 hours ago
All You Need to Know About Syndax (SNDX) Rating Upgrade to Buy
Syndax (SNDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Positive
Zacks Investment Research
21 hours ago
Wall Street Analysts Predict a 237.83% Upside in Syndax (SNDX): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 237.8% in Syndax (SNDX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Neutral
GlobeNewsWire
2 days ago
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second quarter 2025 financial results and provide a business update on Monday, August 4, 2025.
Neutral
Seeking Alpha
3 weeks ago
Syndax Pharmaceuticals: Oversold Pharma Likely To Benefit From Drug Approvals
Syndax now has two approved therapies—NIKTIMVO and Revuforj—but the share price remains under pressure despite these milestones. NIKTIMVO faces a crowded cGVHD market and skepticism about its commercial potential, with analysts projecting modest long-term sales. Revuforj offers significant upside, targeting an underserved leukemia niche with minimal competition and potential for label expansion pending FDA review.
Neutral
GlobeNewsWire
3 weeks ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2025 the Company granted inducement awards to purchase up to 228,400 shares of common stock to 14 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Neutral
GlobeNewsWire
1 month ago
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
– PDUFA action date set for October 25, 2025 – – sNDA being reviewed under FDA's RTOR program – – Revumenib has the potential to become the first and only menin inhibitor approved in both R/R mNPM1 AML and R/R KMT2Ar acute leukemia – NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for its supplemental New Drug Application (sNDA) for Revuforj® (revumenib) for the treatment of relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML). The sNDA is being reviewed under the FDA's Real-Time Oncology Review (RTOR) program and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of October 25, 2025.
Neutral
GlobeNewsWire
1 month ago
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
– Revumenib was generally well-tolerated in combination with venetoclax/azacitidine in older, newly diagnosed mNPM1 and KMT2Ar AML patients –
Neutral
GlobeNewsWire
1 month ago
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
– 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed across subgroups, regardless of co-mutations, number of prior lines of therapy, or prior venetoclax, within efficacy-evaluable pivotal R/R mNPM1 AML population – – 60% (3/5) ORR in Ph 1 patients with R/R NUP98r AML – NEW YORK, June 12, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced new data from the pivotal AUGMENT-101 trial of Revuforj® (revumenib), the Company's first-in-class menin inhibitor, in patients with relapsed or refractory (R/R) mutant NPM1 (mNPM1) and NUP98-rearranged (NUP98r) acute myeloid leukemia (AML). The data are being presented in posters at the 30th European Hematology Association (EHA) Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy and virtually.
Neutral
GlobeNewsWire
1 month ago
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on June 1, 2025 the Company granted inducement awards to purchase up to 119,700 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
Neutral
GlobeNewsWire
2 months ago
Syndax Announces Participation in June Investor Conferences
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
Charts implemented using Lightweight Charts™